BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 25843554)

  • 1. Complications of systemic juvenile idiopathic arthritis: risk factors and management recommendations.
    Woerner A; von Scheven-Gête A; Cimaz R; Hofer M
    Expert Rev Clin Immunol; 2015 May; 11(5):575-88. PubMed ID: 25843554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic JIA: new developments in the understanding of the pathophysiology and therapy.
    Vastert SJ; Kuis W; Grom AA
    Best Pract Res Clin Rheumatol; 2009 Oct; 23(5):655-64. PubMed ID: 19853830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis, the first Chinese experience.
    Qiu L; Ma L; Xie Y; Jin J; Pan Y; Li S; Fan Z; Yu H
    Pediatr Rheumatol Online J; 2024 Mar; 22(1):38. PubMed ID: 38504360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macrophage activation syndrome in the era of biologic therapy.
    Grom AA; Horne A; De Benedetti F
    Nat Rev Rheumatol; 2016 May; 12(5):259-68. PubMed ID: 27009539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-6 blockade in systemic juvenile idiopathic arthritis - achievement of inactive disease and remission (data from the German AID-registry).
    Bielak M; Husmann E; Weyandt N; Haas JP; Hügle B; Horneff G; Neudorf U; Lutz T; Lilienthal E; Kallinich T; Tenbrock K; Berendes R; Niehues T; Wittkowski H; Weißbarth-Riedel E; Heubner G; Oommen P; Klotsche J; Foell D; Lainka E
    Pediatr Rheumatol Online J; 2018 Apr; 16(1):22. PubMed ID: 29622022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Pathways in the Pathogenesis of Systemic Juvenile Idiopathic Arthritis.
    Schulert GS; Kessel C
    Rheum Dis Clin North Am; 2023 Nov; 49(4):895-911. PubMed ID: 37821202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature.
    Sönmez HE; Demir S; Bilginer Y; Özen S
    Clin Rheumatol; 2018 Dec; 37(12):3329-3335. PubMed ID: 29663156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of clinical outcomes in systemic juvenile idiopathic arthritis patients treated with biological agents in Turkey: the TURSIS study.
    Sozeri B; Demir F; Barut K; Atalay E; Pac Kisaarslan A; Özdel S; Altuğ Gücenmez Ö; Makay B; Aktay Ayaz N; Haşlak F; Sağ E; Yıldız M; Kaya Akça Ü; Adroviç A; Bilginer Y; Poyrazoğlu H; Ünsal E; Kasapçopur Ö; Özen S
    Clin Exp Rheumatol; 2024 Jan; 42(1):194-201. PubMed ID: 37497697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of systemic juvenile idiopathic arthritis.
    Hinze CH; Foell D; Kessel C
    Nat Rev Rheumatol; 2023 Dec; 19(12):778-789. PubMed ID: 37923864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of interferon-gamma levels may lead to earlier diagnosing macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
    Lu M; Teng L; Xu Y; Xu X
    Pediatr Rheumatol Online J; 2023 Oct; 21(1):115. PubMed ID: 37828529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant Interleukin-1 Receptor Antagonist Is an Effective First-Line Treatment Strategy in New-Onset Systemic Juvenile Idiopathic Arthritis, Irrespective of HLA-DRB1 Background and IL1RN Variants.
    Erkens RGA; Calis JJA; Verwoerd A; De Roock S; Ter Haar NM; Den Engelsman G; Van der Veken LT; Ernst RF; Van Deutekom HWM; Pickering A; Scholman RC; Jansen MHA; Swart JF; Sinha R; Roth J; Schulert GS; Grom AA; Van Loosdregt J; Vastert SJ
    Arthritis Rheumatol; 2024 Jan; 76(1):119-129. PubMed ID: 37471469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy and safety of canakinumab in the treatment of systemic juvenile idiopathic arthritis in Japanese patients: Results from an open-label Phase III study.
    Iwata N; Nishimura K; Hara R; Imagawa T; Shimizu M; Tomiita M; Umebayashi H; Takei S; Seko N; Wakabayashi R; Yokota S
    Mod Rheumatol; 2023 Nov; 33(6):1162-1170. PubMed ID: 36399020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Canakinumab in the treatment of systemic juvenile idiopathic arthritis: a retrospective single center study in China.
    Zhu X; Weng R; Huang Y; Xu Y; Yang J; He T
    Front Pediatr; 2024; 12():1349907. PubMed ID: 38550627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic juvenile idiopathic arthritis-associated lung disease: A retrospective cohort study.
    Belozerov KE; Solomatina NM; Isupova EA; Kuznetsova AA; Kostik MM
    World J Clin Pediatr; 2024 Mar; 13(1):88912. PubMed ID: 38596441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient characteristics associated with response to NSAID monotherapy in children with systemic juvenile idiopathic arthritis.
    Sura A; Failing C; Sturza J; Stannard J; Riebschleger M
    Pediatr Rheumatol Online J; 2018 Jan; 16(1):2. PubMed ID: 29304824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers in systemic juvenile idiopathic arthritis: a comparison with biomarkers in cryopyrin-associated periodic syndromes.
    Nirmala N; Grom A; Gram H
    Curr Opin Rheumatol; 2014 Sep; 26(5):543-52. PubMed ID: 25050926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-1 Inhibition in Systemic Juvenile Idiopathic Arthritis.
    Giancane G; Minoia F; Davì S; Bracciolini G; Consolaro A; Ravelli A
    Front Pharmacol; 2016; 7():467. PubMed ID: 27999545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment and analysis of a novel diagnostic model for systemic juvenile idiopathic arthritis based on machine learning.
    Ding P; Du Y; Jiang X; Chen H; Huang L
    Pediatr Rheumatol Online J; 2024 Jan; 22(1):18. PubMed ID: 38243323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macrophage activation syndrome in a patient with systemic onset of the juvenile idiopathic arthritis.
    Jain D; Aggarwal HK; Rao A; Mittal A; Jain P
    Reumatologia; 2016; 54(1):42-7. PubMed ID: 27407277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety of canakinumab in systemic juvenile idiopathic arthritis and autoinflammatory diseases in pediatric patients: a multicenter study.
    Coşkuner T; Çağlayan Ş; Akgün Ö; Torun R; Yayla ENS; Bagrul IL; Kılbaş G; Yener GO; Köse H; Öztürk K; Baba Ö; Çakan M; Demir F; Sönmez HE; Kalyoncu M; Kılıç SS; Yüksel S; Bağlan E; Bakkaloğlu SA; Ünsal E; Aktay Ayaz N; Sözeri B
    Expert Opin Biol Ther; 2023; 23(12):1299-1306. PubMed ID: 37970654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.